Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19).
Obstet Gynecol
; 136(5): 1025-1029, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1059683
ABSTRACT
BACKGROUND:
There are limited data regarding treatment options for pregnant women with severe coronavirus disease 2019 (COVID-19). CASE A 35-year-old primigravid patient at 22 weeks of gestation presented with 7 days of fever, cough, anosmia, and dyspnea. Nasopharyngeal swab was positive for the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a chest X-ray demonstrated bilateral patchy infiltrates. Laboratory evaluation was notable for marked elevation of interleukin-6 and C-reactive protein concentrations. On hospital day 3, owing to increased dyspnea and oxygen requirement, the patient was treated with tocilizumab followed by 5 days of remdesivir. She responded well, recovered to room air, and was discharged home after a 9-day hospitalization.CONCLUSION:
Tocilizumab and remdesivir may be effective for treatment of severe COVID-19 in pregnancy, but additional data are needed to guide risk-benefit considerations.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Complicaciones Infecciosas del Embarazo
/
Adenosina Monofosfato
/
Infecciones por Coronavirus
/
Alanina
/
Pandemias
/
Anticuerpos Monoclonales Humanizados
/
Pulmón
Tipo de estudio:
Reporte de caso
/
Estudios diagnósticos
/
Estudio experimental
/
Estudio pronóstico
Límite:
Adulto
/
Femenino
/
Humanos
/
Embarazo
Idioma:
Inglés
Revista:
Obstet Gynecol
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS